Screener
Edgewise Therapeutics, Inc. EWTX Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Edgewise Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Edgewise Therapeutics, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 8:09 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-056713
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Accrued compensation | (6,752) | (6,081) |
| Accrued other expenses and other liabilities | 635 | 122 |
| Lease liability | (196) | (179) |
| Net cash used in operating activities | (42,543) | (37,866) |
| Cash flows from investing activities | ||
| Purchases of marketable securities | (110,152) | (122,180) |
| Sales of marketable securities | 3,966 | 15,000 |
| Maturities of marketable securities | 108,879 | 151,122 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Edgewise Therapeutics, Inc.'s operating cash flow?
- Edgewise Therapeutics, Inc. (EWTX) reported operating cash flow of -$42.54M in Q1 2026.
- How has Edgewise Therapeutics, Inc.'s operating cash flow changed year-over-year?
- Edgewise Therapeutics, Inc.'s operating cash flow decreased by 12.4% year-over-year, from -$37.87M to -$42.54M.
- What is the long-term trend for Edgewise Therapeutics, Inc.'s operating cash flow?
- Over 4 years (2021 to 2025), Edgewise Therapeutics, Inc.'s operating cash flow has grown at a 43.9% compound annual growth rate (CAGR), from -$33.51M to -$143.82M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Edgewise Therapeutics, Inc.'s operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude